Diffuse Large B-Cell Lymphoma of the Central Nervous System. Immunophenotype, Clinicopathological Features and Differential Diagnosis

Mónica Belinda Romero-Guadarrama, María Esther Gutiérrez Díaz-Ceballos, Fiacro Jiménez-Ponce, Samantha Thingen-Velarde

Hemathology Service, Hospital General de México, Mexico City, Mexico.
Mónica Belinda Romero-Guadarrama.
Neurosurgery Unit Hospital General de México, Mexico City, Mexico.
Unit Pathology Hospital General de México, Medicine School, Autonomous University of Mexico, Mexico City, Mexico.

DOI: 10.4236/ojpathology.2012.24024                

Abstract

Background: Diffuse large B-cell lymphomas of the central nervous system (DLBCL CNS) represent less than 1% of all lymphomas and between 2% and 3% of all cerebral tumors. They occur in adults of 60 years of age or more. The objective of this work is to describe the clinical-pathological characteristics, the immunophenotype and the differential diagnosis. Clinical Case: From the files of the surgical pathology unit we found four cases of primary diffuse large B cell lymphoma of the central nervous system in a 6-year period. Three corresponded to women over 47 years of age and the other to a 42-year-old man. The time of evolution was between 2 and 4 months. The symptoms were headache, blurred vision, hemiparesis, and seizures. Localization was in the pineal region, the frontal, parietal regions, and the right thalamus. Morphologically, large lymphoid cells with a diffuse growth pattern and necrosis were observed. Immunohistochemical markers, such as CD 20 and bcl2 were positive, one was positive to CD3. Expression of bcl6 and CD 10 was positive in one case, and MUM-1 was positive in three cases. All the cases were negative for Epstein-Barr virus. Conclusions: The diffuse large-B cell lymphoma of the central nervous system is rare. Its average age of presentation is at 60 years or older. The localization is in the pineal, frontal, parietal and thalamic regions. Three cases were originated by activated B lymphocyte (MUM-1 expression) and other from the Germinal Center (GC) (CD 10 expression). The clinical course was bad. The four patients died shortly after the diagnosis.

Keywords

Primary Lymphoma; Central Nervous System

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	A. C. Feller and J. Diebold, “Histopathology of Nodal and Extranodal Non-Hodgkin’s Lymphomas. Based on the WHO Classification,” 3rd Completely Revised and Updated Edition, Springer-Verlag, Berlin, Heidelberg, New York, 2004, pp. 330-334.
[2]	S. Swerdlow, E. Campo, L. N. Harris, S. E. Jaffe, A. S. Pileri, H. Stein, et al., “WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues,” 4th Edition, International Agency for Research of Cancer, Lyon, 2008, pp. 240-241.
[3]	T. Batchelor and J. S. Loeffler, “Primary CNS Lymphoma,” Journal of Clinical Oncology, Vol. 24, No. 8, 2006, pp. 1281-1288. doi:10.1200/JCO.2005.04.8819
[4]	L. Jiang, A. L. Marlow, J. S. Cooper, V. Ch. Roemeling, M. D. Menke, A. J. Copland, et al., “Selective Central Nervous System Tropism of Primary Central Nervous System Lymphoma,” International Journal of Clinical and Experimental Pathology, Vol. 3, No. 8, 2010, pp. 763-767.
[5]	M. Montesinos-Rongen, S. Reiner and D. Marina, “Primary Lumphoma of the Central Nervous System: Just DLBCL or Not?” Blood, Vol. 113, No. 1, 2009, pp. 7-10. doi:10.1182/blood-2008-04-149005
[6]	F. H. Hochberg and D. C. Miller, “Primary Central Nervous System Lymphoma,” Journal of Neurosurgery, Vol. 68, 1998, pp. 835-853. doi:10.3171/jns.1988.68.6.0835
[7]	T. M. Alécio, J. M. Alécio, P. H. Aguilar and R. Ramina, “Primary Central Nervous System Lymphomas in Immunocompetents Patients,” Neurocirugia, Vol. 17, 2006, pp. 46-53.
[8]	M. Schabet, “Epidemiology of Primary CNS Lymphoma,” Journal of Neuro-Oncology, Vol. 43, No. 3, 1999, pp. 199-201. doi:10.1023/A:1006290032052
[9]	B. Bataille, V. Delwail, E. Menet, P. V. Marcq, P. In- grand, M. Wager, et al., “Primary Intracerebral Malignant Lymphoma. Report of 248 Cases,” Journal of Neuro-Oncology, Vol. 92, No. 2, 2000, pp. 261-266.
[10]	W. Kuker, T. Nagele, A. Korfel, S. Hecky, E. Thiel, M. Bamberg, et al., “Primary Central Nervous System Lymphomas (PCNSL) MRI Features at Presentation in 100 Patients,” Journal of Neuro-Oncology, Vol. 72, No. 2, 2005, pp. 169-177. doi:10.1007/s11060-004-3390-7
[11]	A. Coulon, F. Lafitte, K. Hoang-Xuan, N. Martin-Duverneuil, K. Mokhtari, J. Blustajn, et al., “Radio-Graphic Findings in 37 Patients of Primary CNS Lymphoma in Immunocompetent Patients,” European Radiology, Vol. 12, 2002, pp. 329-340. doi:10.1007/s003300101037
[12]	N. Erdag, R. M. Bhorade, R. A. Alberico, N. Yousuf and M. R. Patel, “Primary Lymphoma of the Central Nervous System: Typical and Atypical CT and MR Imaging Appearances,” American Journal of Roentgenology, Vol. 176, No. 5, 2001, pp. 1319-1326.
[13]	G. Guinto, I. Felix, N. Arechiga, V. Arteaga and K. Kovacs, “PCNSL in Immunocompetent Patients,” Histology and Histopathology, Vol. 19, 2004, pp. 963-972.
[14]	K. M. Braaten, R. A. Betensky, L. de Leval, Y. Okada, F. H. Hochberg, D. N. Lous, et al., “BCL-6 Expression Predicts Improved Survival in Patients with Primary Central Nervous System Lymphoma,” Clinical Cancer Research, Vol. 9, No. 3, 2003, pp. 1063-1069.
[15]	S. Camilleri-Broet, E. Criniere, P. Broet, V. Delwail, K. Mokhtari, A. Moreau, et al., “A Uniform Activated B-Cell-Like Immunophenotype Might Explain the Poor Prognosis of Primary Central Nervous System Lymphomas Analysis of 83 Cases,” Blood, Vol. 107, No. 1, 2006, pp. 190-196. doi:10.1182/blood-2005-03-1024
[16]	C. H. Lin, K. T. Kuo, S. S. Chuang, S. H. Kuo, J. H. Chang, K. C. Chang, et al., “Comparison of the Expression and Prognostic Significance of Differential Markers between Diffuse Large B-Cell Lymphoma of Central Nervous System Origin and Peripheral Nodal Origin,” Clinical Cancer Research, Vol. 12, 2006, pp. 1152-1156. doi:10.1158/1078-0432.CCR-05-1699
[17]	K. M. Algino, R. W. Thomason, D. E. King, M. M. Montiel and F. E. Craig, “CD 20 (Pan-B Cell Antigen) Expression on Bone Marrow Derived T Cells,” American Journal of Clinical Pathology, Vol. 106, No. 1, 1996, pp. 76-81.
[18]	S. J. Hamilton-Dutoit, G. Pallesen, “B Cell Associated Monoclonal Antibody L 26 May Occasionally Label T Cell Lymphomas,” APMIS, Vol. 97, No. 11, 1989, pp. 1033-1036. doi:10.1111/j.1699-0463.1989.tb00514.x
[19]	J. Linder, L. Y. Ye, D. S. Harrington, J. O. Armitage, D. D. Weissenburger, “Monoclonal Antibodies Marking B-Cell Non Hodgkin’s Lymphoma in Paraffin Embedded Tissues,” Modern Pathology, Vol. 1, No. 1, 1988, pp. 29-34.
[20]	D. A. Arber and L. M. Weiss, “CD 43: A Review,” Applied Immunohistochemistry, Vol. 1, 1993, pp. 88-96.
[21]	D. A. Arber and L. M. Weiss, “CD 5: A Review,” Applied Immunohistochemistry, Vol. 3, 1995, pp. 1-22.
[22]	H. S. Khalidi, R. K. Brynes, P. Borwne, C. H. Koo, H. Battifora and L. J. Medeiros, “Intravascular Large B-Cell Lymphoma: The CD 5 Antigen Is Expressed by a Subset of Cases,” Modern Pathology, Vol. 11, No. 10, 1998, pp. 983-988.
[23]	P. J. Kurtin, K. S. Hobday, S. Ziesmer and B. L. Caron, “Demonstration of Distinct Antigen Profiles of Small B-Cell Lymphomas by Paraffin Section Immunohistochemistry,” American Journal of Clinical Pathology, Vol. 112, No. 3, 1999, pp. 319-329.
[24]	T. Inaba, C. Shimazaki, T. Sumikuma, A. Okano, M. Hatsuse and A. Okamoto, “T-Cell Associated Antigen- Positive B-Cell Lymphoma,” Leukemia & Lymphoma, Vol. 42, No. 6, 2001, pp. 1161-1171. doi:10.3109/10428190109097741
[25]	A. Matolcsy, A. Chadburn and D. M. Knowles, “De Novo CD 5 Positive and Richter’s Syndrome-Associated Diffuse Large B Cell Lymphomas Are Genotypically Distinct,” American Journal of Pathology, Vol. 147, No. 1, 1995, pp. 207-216.
[26]	J. Wang, Ch. Chen, S. Lau, R. I. Raghavan, E. H. Rowsell, J. Said, et al., “CD-3 Positive Large B-Cell Lymphoma,” American Journal of Surgical Pathology, Vol. 33, No. 4, 2009, pp. 505-512. doi:10.1097/PAS.0b013e318185d231
[27]	N. Vajpayee, J. Hussain, I. Tolocica, R. E. Hutchison and A. Gajra, “Expression of Signal Transducter and Activator of Transcription 3 (STAT 3) in Primary Central Nervous System Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of 17 Cases,” Journal of Neuro-Oncology, Vol. 100, No. 2, 2010, pp. 294-253. doi:10.1007/s11060-010-0188-7
[28]	A. J. Ferreri, J. Y. Blay, M. Reni, F. Pasini, M. Spina, A. Ambrosetti, et al., “Pronostic Scoring System for Primary CNS Lymphomas: The International Extra-Nodal Study Group Experience,” Journal of Clinical Oncology, Vol. 21, No. 2, 2003, pp. 266-272. doi:10.1200/JCO.2003.09.139
[29]	R. Yamanaka, K. Morii, Y. Shinbo, J. Homma, M. Sano, N. Tsuchiya, et al., “Results of Treatment of 112 Cases of Primary CNS Lymphoma,” Japanese Journal of Clinical Oncology, Vol. 38, No. 5, 2008, pp. 373-380. doi:10.1093/jjco/hyn027